Pharmaceuticals, Biotechnology and Life Sciences
Medicure Inc reported net loss for the quarter ended March 31, 2019 at $2.8 million compared to net income of $1.4 million for the quarter ended March 31, 2018.
Veratrak, a UK-based software provider dedicated to transforming supply chains across the life science industry, said Wednesday in a press release that contract packaging organisation (CPO) Central Pharma has selected its platform to help it achieve digitised end-to-end visibility of its supply chain and improve collaboration.
Eli Lilly’s Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly’s rapid-acting insulin and need a lower-cost option, the company said Wednesday.
Mayne Pharma Group Limited got approval from the USFDA for Sorilux foam, 0.005% in adolescents, for treating plaque psoriasis of the scalp and body in patients 12 years and older.
Halozyme Therapeutics said Wednesday that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.
Debiopharm has enrolled first patient in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors.
The development of the UK’s first dedicated Vaccines Manufacturing Innovation Centre (VMIC) has moved a step closer with the contract to design an advanced array of laboratory and production facilities within a ‘cleanroom wrap’ environment being awarded to WHP, the company has said in a statement.
Verona Pharma posted Monday expanded analysis to positive results from March, from from findings from its chronic obstructive pulmonary disease (“COPD”) clinical trial program with lead product candidate, ensifentrine (RPL554). Positive results from the 4-week, 400-patient Phase 2b study were initially reported in March 2018.
ImaginAb has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County.
Roche study showed entrectinib shrank tumours (objective response rate; ORR) in all children and adolescents who had NTRK, ROS1 or ALK fusion-positive solid tumours (11 of 11 patients), including two patients achieving a complete response.